-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

Benzinga·10/30/2026 16:22:44
Listen to the news
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.